{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:52:13Z","timestamp":1791453133950,"version":"4.3.3"},"reference-count":151,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20231014"],"award-info":[{"award-number":["BK20231014"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20230103"],"award-info":[{"award-number":["BK20230103"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010574","name":"China Academy of Space Technology","doi-asserted-by":"publisher","award":["2021QNRC001"],"award-info":[{"award-number":["2021QNRC001"]}],"id":[{"id":"10.13039\/501100010574","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173741"],"award-info":[{"award-number":["82173741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930100"],"award-info":[{"award-number":["81930100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304309"],"award-info":[{"award-number":["82304309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Innovation"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.xinn.2025.100801","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T11:57:44Z","timestamp":1736855864000},"page":"100801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Global first-in-class drugs approved in 2023\u20132024: Breakthroughs and insights"],"prefix":"10.1016","volume":"6","author":[{"given":"Daichao","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-5644","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xinn.2025.100801_bib1","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/pharmaceutics15071794","article-title":"Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin","volume":"15","author":"Okuyama","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xinn.2025.100801_bib2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cpt.3110","article-title":"The Origin of First-in-Class Drugs: Innovation Versus Clinical Benefit","volume":"115","author":"Osipenko","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.xinn.2025.100801_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/d41573-024-00001-x","article-title":"2023 FDA approvals","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrd1010","article-title":"A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole","volume":"2","author":"Olbe","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40265-024-02056-x","article-title":"Zolbetuximab: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","article-title":"Claudin 18.2 as a novel therapeutic target","volume":"21","author":"Nakayama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2025.100801_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114742","article-title":"A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives","volume":"243","author":"Gu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2025.100801_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/molecules22020279","article-title":"Drug Design and Discovery: Principles and Applications","volume":"22","author":"Zhou","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.xinn.2025.100801_bib9","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.cell.2024.02.040","article-title":"Challenges and opportunities in oncology drug development and clinical research in China","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2025.100801_bib10","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2024.100096","article-title":"Effect of anti-diabetic drugs in primary prevention of cardiovascular disease in type 2 diabetes and prediabetes: A systematic review and meta-analysis of randomized trials","volume":"2","author":"Zhang","year":"2024","journal-title":"Innov. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib11","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1038\/s41467-023-37572-z","article-title":"Improving the generalizability of protein-ligand binding predictions with AI-Bind","volume":"14","author":"Chatterjee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2025.100801_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41573-020-0087-3","article-title":"Improving target assessment in biomedical research: the GOT-IT recommendations","volume":"20","author":"Emmerich","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4155\/fmc-2019-0307","article-title":"An overview of drug discovery and development","volume":"12","author":"Berdigaliyev","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.xinn.2025.100801_bib14","series-title":"Novel Drug Approvals for 2024","year":"2024"},{"key":"10.1016\/j.xinn.2025.100801_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/d41573-022-00058-6","article-title":"Evolution of innovative drug R&D in China","volume":"21","author":"Li","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/d41573-024-00034-2","article-title":"Approvals by the China NMPA in 2023","volume":"23","author":"Zhi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41392-024-01770-y","article-title":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xinn.2025.100801_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/d41573-024-00011-9","article-title":"2023 FDA approvals: unprecedented volume at moderate value","volume":"23","author":"Baedeker","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib19","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.drudis.2022.02.015","article-title":"Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory","volume":"27","author":"Beck","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xinn.2025.100801_bib20","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/pharmaceutics14112538","article-title":"FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis","volume":"14","author":"Benedetto Tiz","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xinn.2025.100801_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xinn.2025.100801_bib22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood-2023-180780","volume":"142","author":"Risitano","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2025.100801_bib24","article-title":"Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment","volume":"132","author":"Szlendak","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101210","article-title":"Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"66","author":"Xu","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.xinn.2025.100801_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/imr.13137","article-title":"The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target","volume":"313","author":"Risitano","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xinn.2025.100801_bib27","series-title":"Danicopan","year":"2024"},{"key":"10.1016\/j.xinn.2025.100801_bib28","first-page":"329","article-title":"FDA approves first complement factor D inhibitor","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib29","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.xinn.2025.100801_bib30","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s40265-022-01806-z","article-title":"Futibatinib: First Approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/acph-2024-0005","article-title":"A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality","volume":"74","author":"Jain","year":"2024","journal-title":"Acta Pharm."},{"key":"10.1016\/j.xinn.2025.100801_bib32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acsmedchemlett.3c00006","article-title":"Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use","volume":"14","author":"Ito","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.xinn.2025.100801_bib33","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/oncolo\/oyad149","article-title":"Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR -Aberrant Tumors","volume":"28","author":"Javle","year":"2023","journal-title":"Oncol."},{"key":"10.1016\/j.xinn.2025.100801_bib34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xinn.2025.100801_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2025.100801_bib36","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s40265-023-01949-7","article-title":"Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib37","article-title":"Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa","volume":"32","author":"Schwieger-Briel","year":"2019","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.xinn.2025.100801_bib38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-022-01709-z","article-title":"Palovarotene: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib39","series-title":"Palovarotene","year":"2024"},{"key":"10.1016\/j.xinn.2025.100801_bib40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fendo.2019.00908","article-title":"Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome","volume":"10","author":"Pignolo","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.xinn.2025.100801_bib41","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.3390\/ijms23136983","article-title":"Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification","volume":"23","author":"Felix-Ilemhenbhio","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xinn.2025.100801_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/biomedicines8090325","article-title":"Clinical Aspects and Current Therapeutic Approaches for FOP","volume":"8","author":"Kitoh","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.xinn.2025.100801_bib43","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.3390\/jcm12155114","article-title":"Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need","volume":"12","author":"Hudu","year":"2023","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib44","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","article-title":"Trofinetide: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib45","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1097\/MJT.0000000000001736","article-title":"Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis","volume":"31","author":"Nguyen","year":"2024","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.xinn.2025.100801_bib46","article-title":"FDA Approved Drug Products: Defencath (taurolidine and heparin) catheter lock solution for central venous catheter instillation use","year":"2023","journal-title":"US Food Drug Administration"},{"key":"10.1016\/j.xinn.2025.100801_bib47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/0091270007299929","article-title":"The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers","volume":"47","author":"Gong","year":"2007","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.xinn.2025.100801_bib49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/d41573-024-00102-7","article-title":"FDA approves first telomerase inhibitor","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib50","first-page":"47","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia","volume":"5","author":"Bruedigam","year":"2024","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xinn.2025.100801_bib51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.xinn.2025.100801_bib53","series-title":"Regulation of Cancer Immune Checkpoints Advances in Experimental Medicine and Biology","first-page":"485","article-title":"Macromolecules and Antibody-Based Drugs","author":"Su","year":"2020"},{"key":"10.1016\/j.xinn.2025.100801_bib54","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2023.100018","article-title":"A new perspective in the research of antibody drug conjugate","volume":"1","author":"Li","year":"2023","journal-title":"Innov. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib55","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41587-023-01962-x","article-title":"FDA approves first-in-class bispecific for multiple myeloma","volume":"41","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2025.100801_bib56","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","article-title":"Talquetamab: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib57","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib58","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2023.283931","article-title":"Talquetamab in multiple myeloma","volume":"109","author":"Liu","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.xinn.2025.100801_bib59","first-page":"775","article-title":"FDA approves first GPRC5D\u00a0\u00d7\u00a0CD3-targeted bispecific for multiple myeloma","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib60","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40265-023-01955-9","article-title":"Pozelimab: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(23)02358-9","article-title":"Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study","volume":"403","author":"Ozen","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.xinn.2025.100801_bib62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1515\/jbcpp-2024-0008","article-title":"Pozelimab, a human monoclonal immunoglobulin for the treatment of CHAPLE disease","volume":"35","author":"Kaur","year":"2024","journal-title":"J.\u00a0Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.xinn.2025.100801_bib63","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib64","series-title":"Pegmolesatide Injection Approved for Marketing by China NMPA","year":"2023"},{"key":"10.1016\/j.xinn.2025.100801_bib65","series-title":"The Global Unique Once-Monthly Peptide-Based Highly Specific EPO Receptor Activator, Granted Approval for Marketing","year":"2023"},{"key":"10.1016\/j.xinn.2025.100801_bib66","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/molecules29030585","article-title":"The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules","volume":"29","author":"De La Torre","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.xinn.2025.100801_bib67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MNH.0000000000000430","article-title":"Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease","volume":"27","author":"Gupta","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.xinn.2025.100801_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102273","article-title":"Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial","volume":"65","author":"Zhang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xinn.2025.100801_bib69","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/10286020.2024.2362376","article-title":"Modeling and biological evaluation of pegmolesatide, a novel and potent erythropoiesis-stimulating agent","volume":"26","author":"Zhou","year":"2024","journal-title":"J.\u00a0Asian Nat. Prod. Res."},{"key":"10.1016\/j.xinn.2025.100801_bib70","first-page":"S260","article-title":"POS-606 Pegmolesatide for the treatment of anemia in CKD patients undergoing dialysis: Interim analysis of a multicenter phase \u2162 trial","volume":"7","author":"Chen","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.xinn.2025.100801_bib71","series-title":"FDA Approves First Enzyme Replacement Therapy for Rare Alpha-Mannosidosis","year":"2023"},{"key":"10.1016\/j.xinn.2025.100801_bib72","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1097\/JS9.0000000000000528","article-title":"Can velmanase alfa be the next widespread potential therapy for alpha-mannosidosis?","volume":"109","author":"Abdul Ghani","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.xinn.2025.100801_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108444","article-title":"Diagnosis of alpha-Mannosidosis: Practical approaches to reducing diagnostic delays in this ultra-rare disease","volume":"142","author":"Santoro","year":"2024","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.xinn.2025.100801_bib74","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/bmj.p978","article-title":"First RSV vaccine for older adults is approved in Europe","volume":"381","author":"Wise","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.xinn.2025.100801_bib75","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3390\/pathogens12101259","article-title":"Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines","volume":"12","author":"Topalidou","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.xinn.2025.100801_bib76","article-title":"First RSV vaccine to protect infants up to 6\u00a0months of age and older adults","year":"2023","journal-title":"Eur. Med. Agency"},{"key":"10.1016\/j.xinn.2025.100801_bib77","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib78","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","article-title":"ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis","volume":"44","author":"Jin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.xinn.2025.100801_bib79","series-title":"Biogen\u2019s QALSODY\u00ae (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP","year":"2024"},{"key":"10.1016\/j.xinn.2025.100801_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neurol.2022.09.001","article-title":"Treatment of hereditary amyotrophic lateral sclerosis","volume":"179","author":"Corcia","year":"2023","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.xinn.2025.100801_bib81","article-title":"China enters CAR-T cell therapy era","volume":"3","author":"Cao","year":"2022","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2025.100801_bib82","article-title":"Alzheimer\u2019s disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling","volume":"5","author":"Tao","year":"2024","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2025.100801_bib83","article-title":"Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges","volume":"3","author":"Shen","year":"2022","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2025.100801_bib84","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-life.2023.100043","article-title":"Innovative drugs bring continuous benefits to cancer patients","volume":"1","author":"Huang","year":"2023","journal-title":"Innov. Life"},{"key":"10.1016\/j.xinn.2025.100801_bib85","first-page":"1","volume":"1","year":"2020","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.xinn.2025.100801_bib86","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-life.2023.100014","article-title":"RXR signaling targeted cancer therapy","volume":"1","author":"Zhao","year":"2023","journal-title":"Innov. Life"},{"key":"10.1016\/j.xinn.2025.100801_bib87","article-title":"Therapy of Primary Liver Cancer","volume":"1","author":"Feng","year":"2020","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2025.100801_bib88","article-title":"Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations","volume":"5","author":"Wang","year":"2024","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2025.100801_bib89","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2024.100094","article-title":"Crosstalk between bladder cancer and the tumor microenvironment: Molecular mechanisms and targeted therapy","volume":"2","author":"Lu","year":"2024","journal-title":"Innov. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib90","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-024-02002-x","article-title":"Nirogacestat: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib91","doi-asserted-by":"crossref","DOI":"10.1177\/20363613231182485","article-title":"Nirogacestat and its potential impact on desmoid tumor","volume":"15","author":"Rohail","year":"2023","journal-title":"Rare Tumors"},{"key":"10.1016\/j.xinn.2025.100801_bib92","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-Secretase Inhibitor for Desmoid Tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib93","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-024-02004-9","article-title":"Aponermin: First Approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib94","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ceb.2010.08.001","article-title":"Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation","volume":"22","author":"Yang","year":"2010","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.xinn.2025.100801_bib95","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood.2020008734","article-title":"How I treat relapsed multiple myeloma","volume":"139","author":"Kastritis","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xinn.2025.100801_bib96","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1186\/s12885-023-11489-8","article-title":"Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"23","author":"Xia","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xinn.2025.100801_bib97","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: First Approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib98","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab Plus Chemotherapy in Non\u2013Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xinn.2025.100801_bib99","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41587-024-02451-5","volume":"42","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2025.100801_bib100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmed.2023.12.002","article-title":"Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia","volume":"30","author":"Pilotto","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41582-024-00957-9","article-title":"Approval of omaveloxolone for Friedreich ataxia","volume":"20","author":"Boesch","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.xinn.2025.100801_bib102","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s12311-023-01568-8","article-title":"A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia","volume":"23","author":"Subramony","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.xinn.2025.100801_bib103","first-page":"258","article-title":"FDA approves first Friedreich\u2019s ataxia drug","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13543784.2023.2173063","article-title":"Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia","volume":"32","author":"Profeta","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib105","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure Medications for Adults With Epilepsy: A Review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.xinn.2025.100801_bib106","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2025.100801_bib107","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40265-022-01724-0","article-title":"Ganaxolone: First Approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib108","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2174\/1570159X20666220706102708","article-title":"Epilepsy and Cognitive Impairment in Childhood and Adolescence: A Mini-Review","volume":"21","author":"Operto","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.xinn.2025.100801_bib109","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/0929867330666230320123952","article-title":"Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder","volume":"31","author":"De","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.xinn.2025.100801_bib110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tips.2022.11.007","article-title":"Ganaxolone for management of seizures associated with CDKL5 deficiency disorder","volume":"44","author":"Yasmen","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.xinn.2025.100801_bib111","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/jpet.123.001816","article-title":"Neurosteroids as Novel Anticonvulsants for Refractory Status Epilepticus and Medical Countermeasures for Nerve Agents: A 15-Year Journey to Bring Ganaxolone from Bench to Clinic","volume":"388","author":"Reddy","year":"2024","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.xinn.2025.100801_bib112","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40263-023-01027-2","article-title":"New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System","volume":"37","author":"Perucca","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib113","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1474-4422(19)30029-8","article-title":"The global burden of neurological disorders","volume":"18","author":"Carroll","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xinn.2025.100801_bib114","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40265-021-01527-9","article-title":"Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or \u03b2-Thalassaemia","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40265-019-01251-5","article-title":"Luspatercept: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib116","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41375-022-01521-4","article-title":"Luspatercept for myelodysplastic syndromes\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","volume":"36","author":"Komrokji","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.xinn.2025.100801_bib117","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1038\/s41375-023-02031-7","article-title":"Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts","volume":"37","author":"Platzbecker","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.xinn.2025.100801_bib118","first-page":"8","article-title":"FDA approves first chikungunya vaccine","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib119","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41587-023-02071-5","volume":"41","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2025.100801_bib120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1473-3099(24)00510-3","article-title":"First immunogenicity and safety data on live chikungunya vaccine in an endemic area","volume":"25","author":"Freedman","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xinn.2025.100801_bib121","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(23)00641-4","article-title":"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"401","author":"Schneider","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2025.100801_bib122","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/d41573-023-00177-8","article-title":"Trends in rare disease drug development","volume":"23","author":"Chen","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib123","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baab012","article-title":"Post-translational modifications in proteins: resources, tools and prediction methods","volume":"2021","author":"Ramazi","year":"2021","journal-title":"Database"},{"key":"10.1016\/j.xinn.2025.100801_bib124","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/10600280241241531","article-title":"Capivasertib: A Novel AKT Inhibitor Approved for\u00a0Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer","volume":"58","author":"Luboff","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.xinn.2025.100801_bib125","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","article-title":"Capivasertib: First Approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib126","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xinn.2025.100801_bib127","first-page":"274","article-title":"A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region","volume":"254","author":"Bellacosa","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.xinn.2025.100801_bib128","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1073\/pnas.74.7.3065","article-title":"Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma","volume":"74","author":"Staal","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xinn.2025.100801_bib129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","article-title":"The emerging role of capivasertib in breast cancer","volume":"63","author":"Andrikopoulou","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.xinn.2025.100801_bib130","series-title":"FDA and EMA Accept Regulatory Submission for Pfizer\u2019s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata","year":"2022"},{"key":"10.1016\/j.xinn.2025.100801_bib131","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40265-023-01956-8","article-title":"Correction to: Ritlecitinib: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib132","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.xinn.2025.100801_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2025.100801_bib135","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2025.100801_bib136","series-title":"Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL","year":"2023"},{"key":"10.1016\/j.xinn.2025.100801_bib137","series-title":"Golidocitinib Approved in China as First-In-Class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma","year":"2024"},{"key":"10.1016\/j.xinn.2025.100801_bib138","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xinn.2025.100801_bib139","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: First Approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40265-024-02036-1","article-title":"Drugs in Development to Treat IgA Nephropathy","volume":"84","author":"Del Vecchio","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.xinn.2025.100801_bib141","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA Nephropathy: A Rapidly Evolving Field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.xinn.2025.100801_bib142","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.xinn.2025.100801_bib143","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","article-title":"Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy","volume":"20","author":"Trachtman","year":"2024","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.xinn.2025.100801_bib144","first-page":"1603","article-title":"FDA Approves Novel Schizophrenia Drug","volume":"332","author":"Anderer","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xinn.2025.100801_bib145","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2025.100801_bib146","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.xinn.2025.100801_bib147","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/2472555220926920","article-title":"CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets","volume":"25","author":"Rubbini","year":"2020","journal-title":"SLAS Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib148","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib149","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2025.100801_bib151","series-title":"Johnson\u00a0& Johnson Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes","year":"2024"},{"key":"10.1016\/j.xinn.2025.100801_bib152","series-title":"Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain","year":"2024"},{"key":"10.1016\/j.xinn.2025.100801_bib153","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(23)02697-1","article-title":"Gepotidacin, a new first-in-class antibiotic for treating uncomplicated urinary tract infection","volume":"403","author":"Ali","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xinn.2025.100801_bib154","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/GME.0000000000002138","article-title":"Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)","volume":"30","author":"Simon","year":"2023","journal-title":"Menopause"}],"container-title":["The Innovation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675825000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675825000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:07:38Z","timestamp":1778922458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666675825000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":151,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666675825000049"],"URL":"https:\/\/doi.org\/10.1016\/j.xinn.2025.100801","relation":{},"ISSN":["2666-6758"],"issn-type":[{"value":"2666-6758","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global first-in-class drugs approved in 2023\u20132024: Breakthroughs and insights","name":"articletitle","label":"Article Title"},{"value":"The Innovation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xinn.2025.100801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Youth Innovation Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100801"}}